Ustekinumab, which inhibits the activation of immune cells by interleukins 12 and 23, is recommended for adults with a psoriasis area severity index (PASI) score of 10 or more and a dermatology life quality index (DLQI) score greater than 10.
NICE's approval is contingent on Stelara's manufacturer, Janssen-Cilag, providing the 90mg dose-needed in people who weigh more than 100kg-at the same total cost as a single 45mg vial.
Treatment with ustekinumab should be stopped if an adequate response is not achieved by 16 weeks. An adequate response is defined as either a 75% reduction in PASI score, or a 50% reduction in PASI score accompanied by a 5-point reduction in DLQI score.
Physicians may need to adjust the DLQI score if the patient has any disabilities or communication difficulties that could affect the assessment.